November 21, 2013 / 11:29 AM / 4 years ago

BRIEF-Oncolytics announces data from late-stage head and neck cancer trial

Nov 21 (Reuters) - Oncolytics Biotech Inc : * Biotech inc. announces positive top-line data from reo 018 randomized study

of Reolysin in head and neck cancers * Analysis of patients showed a median overall survival of 150 days in the test

arm versus 115 days in the control arm * Side effects experienced by patients in the test arm of the study were

consistent with expectations * Fewer patients required dose reductions of paclitaxel due to neuropathy or

neurotoxicity on the test arm than the control arm * Of 86 patients with measurable disease at first post-treatment scan, test arm

had a statistically significant increase in tumour shrinkage * Investigators reported a statistically significant increase in patients on

test arm experiencing mild fever, chills, nausea, and diarrhea * Source text for Eikon * Further company coverage

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below